

R 230010Z JAN 06

FM CMC WASHINGTON DC(UC)

TO AL MARADMIN(UC)

UNCLASSIFIED//

MARADMIN 033/06

MSGID/GENADMIN/CMC WASHINGTON DC PPO//

SUBJ/CONTINUATION OF THE ANTHRAX VACCINE IMMUNIZATION PROGRAM (AVIP)//

REF/A/DOC/FDA/191344ZDEC2005// REF/B/DOC/ASD (HA)/221344ZDEC2005//

REF/C/MSG/CMC/161700ZMAY2005// REF/D/MSG/CMC/281800ZJUL2005//

POC/BETHEL D.A./LTCOL/HQMC PPO POC/-/TEL:(703) 692-4369

/EMAIL:BETHELDA@HQMC.USMC.MIL// NARR/REF A IS FDA DOCKET NO. 1980-0208,

BIOLOGICAL PRODUCTS; BACTERIAL VACCINES AND TOXOIDS; IMPLEMENTATION OF

EFFICACY REVIEW; ANTHRAX VACCINE ADSORBED; FINAL ORDER. FEDERAL

REGISTER 2005; VOLUME 70 (DEC 19).

[WWW.FDA.GOV/CBER/RULES/BVACTOXANTH.HTM](http://WWW.FDA.GOV/CBER/RULES/BVACTOXANTH.HTM)

REF B IS ASD (HA) MEMO, CONTINUATION OF THE ANTHRAX VACCINE

IMMUNIZATION PROGRAM (AVIP) REF C IS MARADMIN 230/05, RESUMPTION OF THE ANTHRAX VACCINE IMMUNIZATION PROGRAM (AVIP) UNDER THE EUA.

REF D IS MARADMIN 342/05, EMERGENCY USE AUTHORIZATION (EUA) FOR ANTHRAX

IMMUNIZATIONS /EXTENDED// GENTEXT/REMARKS/REMARKS/1. ON 19 DEC 05,

OFFICIALS FROM THE FOOD AND DRUG ADMINISTRATION (FDA) ISSUED A FINAL

ORDER (REF A), FINDING THAT THE ANTHRAX VACCINE PROTECTS AGAINST ALL

ROUTES OF EXPOSURE TO ANTHRAX SPORES, INCLUDING INHALATION. AFTER

EVALUATION OF THE FULL SCIENTIFIC LITERATURE AND ASSESSING COMMENTS

FROM THE PUBLIC, WHICH WERE SUBMITTED IN EARLY 2005, THE FDA REAFFIRMED

ITS PREVIOUS CONCLUSIONS. AS THIS REGULATORY ACTION REMOVED THE BASIS

AND NEED FOR THE EMERGENCY USE AUTHORIZATION (EUA) THAT DOD HAS

FOLLOWED SINCE APRIL 2005, IT WILL NOT BE NECESSARY FOR DOD TO SEEK

RENEWAL OF THE EUA FOR USE OF ANTHRAX VACCINE TO PREVENT INHALATION

ANTHRAX.

THE CURRENT EUA EXPIRED JANUARY 14, 2006.

2. THE PERIODIC REPORTING REQUIREMENTS (NOW MONTHLY) REMAIN IN EFFECT.

UNTIL THE COURTS COMPLETE THEIR JUDICIAL REVIEW AND WHILE OUR SENIOR

CIVILIAN LEADERS COMPLETE A POLICY REVIEW, DOD WILL CONTINUE VOLUNTARY

ANTHRAX VACCINATIONS (REF B) FOR THOSE SAME PERSONNEL THAT WERE

ELIGIBLE UNDER THE EUA, UTILIZING THOSE REQUIREMENTS STIPULATED IN

REFERENCES C AND D. THIS INTERIM APPROACH WILL CONTINUE TO INCLUDE

EDUCATIONAL BRIEFINGS, AN OPTION TO REFUSE, AND REPORTING REQUIREMENTS

(REF C AND D). THE REQUIREMENT FOR AN "EUA COMPLIANCE OFFICER" (REF C

AND D) REMAINS WITH THE DUTY RENAMED "AVIP COMPLIANCE OFFICER".

ADDITIONALLY, THE CURRENT AVIP TRIFOLD BROCHURE, DATED 16 DEC 05, WILL

BE DISTRIBUTED TO ALL PERSONNEL RECEIVING THE ANTHRAX BRIEFING PRIOR TO

THEIR DECISION TO ACCEPT OR DECLINE THE VACCINE (REF C AND D). TRIFOLDS

WILL BE SHIPPED WITH VACCINE ORDERS TO REQUESTING COMMANDS, OR MAY BE

DOWNLOADED AT [WWW.ANTHRAX.MIL](http://WWW.ANTHRAX.MIL), OR ORDERED VIA EMAIL MESSAGE TO

USAMMADOC@DET.AMEDD.ARMY.MIL 3. POCs FOR THIS MESSAGE ARE:

A. HQMC (PP&O); LTCOL D. A. BETHEL, SERVICE POC (703) 692-4369 (DSN

222) AND MR. F. J. LEPE, ASST SERVICE POC (703) 614-5157 (DSN 224).

B. HQMC (HS); CDR D. L. MCMILLAN (USN), PMO, (703) 614-4478 (DSN

224).

C. HQMC (I&L/LPCD); LCDR SCOTT M SPRATT AND HMC (FMF/SW) PALMARES,

MEDICAL LOGISTICS (703) 695-8926 (DSN 225).

4. COMMAND AND SIGNAL. THIS MARADMIN IS EFFECTIVE IMMEDIATELY UPON

RECEIPT AND APPLIES TO THE MARINE CORPS TOTAL FORCE. THERE IS NO

EXPIRATION DATE AT THIS TIME.//

